3/27
01:09 pm
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $105.00 price target on the stock.
3/19
09:13 am
kros
Morphic appoints Simon Cooper as CMO [Seeking Alpha]
Medium
Report
Morphic appoints Simon Cooper as CMO [Seeking Alpha]
3/19
08:13 am
kros
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer [Yahoo! Finance]
3/18
03:11 pm
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $100.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $100.00 price target on the stock.
3/14
08:12 am
kros
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes [Yahoo! Finance]
Medium
Report
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes [Yahoo! Finance]
3/14
08:00 am
kros
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
Medium
Report
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
3/5
08:10 am
kros
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference [Yahoo! Finance]
Medium
Report
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference [Yahoo! Finance]
3/5
08:00 am
kros
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
Medium
Report
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
3/1
08:14 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
2/29
11:12 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $86.00 price target on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $86.00 price target on the stock.
2/28
04:53 pm
kros
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 [Yahoo! Finance]
Low
Report
Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 [Yahoo! Finance]
2/28
04:13 pm
kros
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/28
04:01 pm
kros
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2/21
07:27 am
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Low
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
1/29
08:09 am
kros
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress [Yahoo! Finance]
Low
Report
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress [Yahoo! Finance]
1/29
08:00 am
kros
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
Low
Report
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
1/25
06:57 am
kros
Humana Stock Falls After Shock Loss and Grim Outlook. Blame Medicare Advantage. [Yahoo! Finance]
Low
Report
Humana Stock Falls After Shock Loss and Grim Outlook. Blame Medicare Advantage. [Yahoo! Finance]
1/25
06:00 am
kros
Keros Therapeutics, Inc. (NASDAQ:KROS) institutional owners may be pleased with recent gains after 2.4% loss over the past year [Yahoo! Finance]
Low
Report
Keros Therapeutics, Inc. (NASDAQ:KROS) institutional owners may be pleased with recent gains after 2.4% loss over the past year [Yahoo! Finance]
1/24
10:51 am
kros
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
1/23
11:41 am
kros
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
Low
Report
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy? [Yahoo! Finance]
1/9
08:00 am
kros
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
Low
Report
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
1/3
10:02 pm
kros
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $86.00 price target on the stock.
High
Report
Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $86.00 price target on the stock.
1/3
09:29 pm
kros
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
High
Report
Keros Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
1/3
04:14 pm
kros
Keros Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
High
Report
Keros Therapeutics Announces Proposed Public Offering of Common Stock [Yahoo! Finance]
1/3
04:05 pm
kros
Keros Therapeutics Announces Proposed Public Offering of Common Stock
High
Report
Keros Therapeutics Announces Proposed Public Offering of Common Stock